View Future GrowthRevium Rx 過去の業績過去 基準チェック /06Revium Rxの収益は年平均-69.2%で減少しているが、Pharmaceuticals業界はgrowingで9.7%年平均の収益となった。主要情報-69.23%収益成長率-39.01%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率n/a株主資本利益率-219.95%ネット・マージンn/a前回の決算情報31 Mar 2026最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Oct 22Revium Recovery Inc. Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant InfectionsRevium Rx announced significant progress in its regulatory and manufacturing programs supporting the planned Phase 1 clinical trial of its lead product candidate, Nano-Mupirocin - a novel systemic formulation of the well-known and highly potent antibiotic mupirocin. Last month, the company submitted its clinical trial application to the Israeli Ministry of Health, marking a critical milestone toward the initiation of first-in-human studies in early 2026. Concurrently, Revium Rx, in collaboration with WuXi AppTec, one of the world's leading global CDMOs, continues to advance the scale-up and production of its GMP clinical batch, with final release expected by the end of 2025. Addressing the Urgent Threat of Antimicrobial Resistance (AMR) In 2021, Methicillin-Resistant Staphylococcus Aureus (MRSA) was estimated to have caused approximately 130,000 deaths directly attributable to antimicrobial resistance (AMR) -- a sharp rise from 57,200 in 1990. According to the Global Research on Antimicrobial Resistance (GRAM) Project published in The Lancet in 2022, MRSA was responsible for over 100,000 AMR-attributable deaths in 2019, making it one of the deadliest pathogens that year. The global AMR therapeutics market was valued at USD 8.7 billion in 2023 and is projected to exceed USD 12.5 billion by 2030, growing at a CAGR of 5.3 %, according to Grand View Research, 2024. Within this rapidly expanding global market, Nano-Mupiroci targets several high-value infectious disease indications, including Methicillin-ResistantStaphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and Ceftriaxone-Resistant Gonorrhea (CR-Gonorrhea). If Nano-Mupirocin demonstrates favorable results in clinical trials, of which no assurance can be provided, the Company will seek to capture a meaningful share within this rapidly expanding market, reflecting both the urgent clinical need and the significant commercial potential of novel antibiotics effective against resistant pathogens.お知らせ • Feb 14Revium Recovery Inc. has filed an IPO in the amount of $5 million.Revium Recovery Inc. has filed an IPO in the amount of $5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,562,500 Price\Range: $3.2 Discount Per Security: $0お知らせ • Feb 06Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million. Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd. on February 4, 2025.お知らせ • Dec 22Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million.収支内訳Revium Rx の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:RVRC 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 260-142231 Dec 250-132230 Sep 250-22230 Jun 250-22231 Mar 250-22231 Dec 240-41231 Dec 230001質の高い収益: RVRCは現在利益が出ていません。利益率の向上: RVRCは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: RVRCは利益が出ておらず、過去 5 年間で損失は年間69.2%の割合で増加しています。成長の加速: RVRCの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: RVRCは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。株主資本利益率高いROE: RVRCは現在利益が出ていないため、自己資本利益率 ( -219.95% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 22:13終値2026/03/30 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Revium Rx. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Oct 22Revium Recovery Inc. Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant InfectionsRevium Rx announced significant progress in its regulatory and manufacturing programs supporting the planned Phase 1 clinical trial of its lead product candidate, Nano-Mupirocin - a novel systemic formulation of the well-known and highly potent antibiotic mupirocin. Last month, the company submitted its clinical trial application to the Israeli Ministry of Health, marking a critical milestone toward the initiation of first-in-human studies in early 2026. Concurrently, Revium Rx, in collaboration with WuXi AppTec, one of the world's leading global CDMOs, continues to advance the scale-up and production of its GMP clinical batch, with final release expected by the end of 2025. Addressing the Urgent Threat of Antimicrobial Resistance (AMR) In 2021, Methicillin-Resistant Staphylococcus Aureus (MRSA) was estimated to have caused approximately 130,000 deaths directly attributable to antimicrobial resistance (AMR) -- a sharp rise from 57,200 in 1990. According to the Global Research on Antimicrobial Resistance (GRAM) Project published in The Lancet in 2022, MRSA was responsible for over 100,000 AMR-attributable deaths in 2019, making it one of the deadliest pathogens that year. The global AMR therapeutics market was valued at USD 8.7 billion in 2023 and is projected to exceed USD 12.5 billion by 2030, growing at a CAGR of 5.3 %, according to Grand View Research, 2024. Within this rapidly expanding global market, Nano-Mupiroci targets several high-value infectious disease indications, including Methicillin-ResistantStaphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and Ceftriaxone-Resistant Gonorrhea (CR-Gonorrhea). If Nano-Mupirocin demonstrates favorable results in clinical trials, of which no assurance can be provided, the Company will seek to capture a meaningful share within this rapidly expanding market, reflecting both the urgent clinical need and the significant commercial potential of novel antibiotics effective against resistant pathogens.
お知らせ • Feb 14Revium Recovery Inc. has filed an IPO in the amount of $5 million.Revium Recovery Inc. has filed an IPO in the amount of $5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,562,500 Price\Range: $3.2 Discount Per Security: $0
お知らせ • Feb 06Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million. Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd. on February 4, 2025.
お知らせ • Dec 22Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million.